Abstract
Dietary intakes of tomatoes and tomato products containing lycopene have been shown to be associated with decreased risk of chronic diseases, such as cancer. Although several mechanisms, including modulation of gap junction communication and enhancement of immune system, are thought to be implicated in its beneficial activities, evidence is accumulating to suggest that lycopene may act as a modulator of intracellular reactive oxygen species (ROS) and, therefore, control ROS-mediated cell growth. According with this, at high concentration, ROS have been reported to be hazardous for living organisms, whereas at moderate concentrations, they play an important role as regulatory mediators in signaling processes regulating cell growth. In this review, we report the available evidence on a role of lycopene as a redox agent in cell proliferation, differentiation and apoptosis. In particular, we focused our attention on lycopene prevention of cell oxidative damage and its influence in cell growth as well as on lycopene modulation of redox-sensitive molecular targets in cell signalling: growth factors and growth factor receptors, antioxidant response elements, MAPKs, transcription factors, such as NF-κB and AP-1, and cytokine expression. Moreover, we speculate on the possible influence that lycopene may have as a redox agent in cancer.
Keywords: Lycopene, tomato/tomato products, ROS, oxidative damage, redox-sensitive molecular pathways, cell growth, cancer, cell culture and animal studies, human trials
Current Medicinal Chemistry
Title: Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention
Volume: 18 Issue: 12
Author(s): P. Palozza, N. Parrone, R. Simone and A. Catalano
Affiliation:
Keywords: Lycopene, tomato/tomato products, ROS, oxidative damage, redox-sensitive molecular pathways, cell growth, cancer, cell culture and animal studies, human trials
Abstract: Dietary intakes of tomatoes and tomato products containing lycopene have been shown to be associated with decreased risk of chronic diseases, such as cancer. Although several mechanisms, including modulation of gap junction communication and enhancement of immune system, are thought to be implicated in its beneficial activities, evidence is accumulating to suggest that lycopene may act as a modulator of intracellular reactive oxygen species (ROS) and, therefore, control ROS-mediated cell growth. According with this, at high concentration, ROS have been reported to be hazardous for living organisms, whereas at moderate concentrations, they play an important role as regulatory mediators in signaling processes regulating cell growth. In this review, we report the available evidence on a role of lycopene as a redox agent in cell proliferation, differentiation and apoptosis. In particular, we focused our attention on lycopene prevention of cell oxidative damage and its influence in cell growth as well as on lycopene modulation of redox-sensitive molecular targets in cell signalling: growth factors and growth factor receptors, antioxidant response elements, MAPKs, transcription factors, such as NF-κB and AP-1, and cytokine expression. Moreover, we speculate on the possible influence that lycopene may have as a redox agent in cancer.
Export Options
About this article
Cite this article as:
Palozza P., Parrone N., Simone R. and Catalano A., Role of Lycopene in the Control of ROS-Mediated Cell Growth: Implications in Cancer Prevention, Current Medicinal Chemistry 2011; 18 (12) . https://dx.doi.org/10.2174/092986711795496845
DOI https://dx.doi.org/10.2174/092986711795496845 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bisacylimidoselenocarbamates Cause G2/M Arrest Associated with the Modulation of CDK1 and Chk2 in Human Breast Cancer MCF-7 Cells
Current Medicinal Chemistry Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design A Challenge for Medicinal Chemistry by the 17β-hydroxysteroid Dehydrogenase Superfamily: An Integrated Biological Function and Inhibition Study
Current Topics in Medicinal Chemistry Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Familial Colorectal Cancer Type X
Current Genomics Laparoscopic Approach for Surgical Staging in Early Endometrial Cancer
Current Women`s Health Reviews Treatment of Uterine Carcinomas
Current Cancer Therapy Reviews Protein Knockdown Technology: Application of Ubiquitin Ligase to Cancer Therapy
Current Cancer Drug Targets Clinical Aspects of Clara Cell 10-kDa Protein / Uteroglobin (Secretoglobin 1A1)
Current Pharmaceutical Design Small Molecular Inhibitors of p-STAT3: Novel Agents for Treatment of Primary and Metastatic CNS Cancers
Recent Patents on CNS Drug Discovery (Discontinued) Recent Patents Related to Phosphorylation Signaling Pathway on Cancer
Recent Patents on DNA & Gene Sequences Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Challenges in Managing Amniotic Fluid Embolism: An Up-to-Date Perspective on Diagnostic Testing with Focus on Novel Biomarkers and Avenues for Future Research
Current Pharmaceutical Biotechnology Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture Gestational Trophoblastic Neoplasia, an Ancient Disease: New Light and Potential Therapeutic Targets
Anti-Cancer Agents in Medicinal Chemistry Targeting CD147 is a Novel Strategy for Antitumor Therapy
Current Pharmaceutical Design Variances in the Level of COX-2 and iNOS in Different Grades of Endometrial Cancer
Current Pharmaceutical Biotechnology Effect of DNA Repair Deficiencies on the Cytotoxicity of Drugs Used in Cancer Therapy - A Review
Current Medicinal Chemistry Selective Estrogen Receptor Modulators. Current and Future Treatment Options for Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cancer Chemoprevention by Targeting the Epigenome
Current Drug Targets